ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
1000 patient Phase III study required for Armetheon before FDA approval
February 13, 2017Armetheon has reached agreement with the US Food and Drug Administration (FDA) for a single 1000 patient final pivotal trial for its drug candidate, tecarfarin, prior to filing an NDA, which is currently projected to occur in 2019. -
Armetheon to Conduct a 1000 Patient Single Phase 3 Study Prior to NDA Filing for its Novel Oral Anti
February 13, 2017Armetheon, Inc., a specialty pharmaceutical company developing novel small molecule drugs for cardiovascular diseases, has reached agreement with the U.S.
Pharma Sources Insight January 2025
